Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

27.79 -0.29 (-1.03%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 70% Today? ↗

September 08, 2022

Amylyx Pharmaceuticals (AMLX) stock is rocketing higher on Thursday following an update from the FDA on its ALS treatment.

Via InvestorPlace

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS

September 07, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Stock Trading Halted Today

September 07, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate ↗

September 06, 2022

Via Benzinga

The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff ↗

September 02, 2022

The FDA's advisors will meet Wednesday to discuss the experimental ALS treatment.

Via Investor's Business Daily

Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up — Again ↗

July 05, 2022

Could this FDA action turn things around for Amylyx in September?

Via Investor's Business Daily

Here's How Citi Views Amylyx Pharma ↗

June 14, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Amylyx Pharma ↗

June 14, 2022

Within the last quarter, Amylyx Pharma (NASDAQ:AMLX) has observed the following analyst ratings:

Via Benzinga

Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday ↗

September 06, 2022

Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results.

Via Benzinga

Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035

September 02, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Why Stealth BioTherapeutics Shares Are Surging Today? ↗

June 08, 2022

Via Benzinga

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 11, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029

August 11, 2022

Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...

Via FinancialNewsMedia

Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022

August 03, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

7 Biotech Stocks to Buy for Q3 ↗

July 18, 2022

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

Via InvestorPlace

Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases

July 18, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases

July 06, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Why Is Novavax (NVAX) Stock Rallying Today? ↗

July 05, 2022

Novavax (NVAX) stock is taking off on Tuesday after the vaccine company got approval for the expanded use of its Covid-19 vaccine in Europe.

Via InvestorPlace

Amylyx (AMLX) Stock Spikes 13% as FDA Resumes Discussion of ALS Drug ↗

July 05, 2022

A new wrinkle in the story of Amylyx Pharmaceuticals' ongoing battle against ALS bodes well for patients, and for AMLX stock holders.

Via InvestorPlace

Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session ↗

July 05, 2022

Gainers Ra Medical Systems, Inc. (NASDAQ: RMED) shares jumped 69.6% to $0.5240 after the company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter.

Via Benzinga

Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022

July 05, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗

June 28, 2022

Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before.

Via Investor's Business Daily

Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September ↗

June 13, 2022

The Canadian government has given its approval to AMX0035, a new drug from Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc.

Via Benzinga

Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS

June 13, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026

June 22, 2022

Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...

Via FinancialNewsMedia

82 Biggest Movers From Yesterday ↗

June 15, 2022

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.

Via Benzinga

83 Biggest Movers From Yesterday ↗

June 09, 2022

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...

Via Benzinga

69 Biggest Movers From Friday ↗

June 06, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.